MedTrace Logo

CAR-T-19 Injection in the Treatment of CD19-positive Relapsed/Refractory B-ALL

NCT06179524 · Status: RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 100

Last updated 2025-01-13

No results posted yet for this study

Summary

This is a phase II clinical study to evaluate the safety and efficacy of CAR-T-19 injection in the treatment of CD19-positive relapsed/refractory B-cell acute lymphoblastic leukemia.

Conditions

  • Relapsed B-cell Acute Lymphoblastic Leukemia
  • Refractory B-cell Acute Lymphoblastic Leukemia

Interventions

BIOLOGICAL

CAR-T-19 cell injection

The functional component of CAR-T-19 cell injection is T cells that have been genetically modified to express anti CD19 chimeric antigen receptors.

Sponsors & Collaborators

  • Beijing Yongtai Ruike Biotechnology Company Ltd

    lead INDUSTRY

Principal Investigators

  • Xiaofan Zhu · Hematology Hospital of the Chinese Academy of Medical Sciences

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Max Age
25 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-01-03
Primary Completion
2025-06-30
Completion
2027-04-30

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06179524 on ClinicalTrials.gov